Pfizer laid the blame on the rising R&D costs, increasing generic competition and tougher drug regulations for its restructuring operations in France.
The global pharmaceutical industry has seen a large number of job cuts in the recent times. Previously, GSK cut its sales force by 1,000 while Novartis axed 550 sales jobs. Merck, Wyeth and Bristol-Myers Squibb Co have also trimmed their workforce.